Zobrazeno 1 - 10
of 4 099
pro vyhledávání: '"6.1 Pharmaceuticals"'
Autor:
Fallara, Giuseppe, Robesti, Daniele, Raggi, Daniele, Montorsi, Francesco, Necchi, Andrea, Cooperberg, Matthew R, Malavaud, Bernard, Ploussard, Guillaume, Martini, Alberto
Publikováno v:
European Urology Open Science. 52:40-43
The PROpel trial assessed the combination of olaparib+abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer
Publikováno v:
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, vol 33, iss 3
ObjectiveInflammation may be present with chronic kidney disease CKD and diet composition high in protein intake and fats may affect inflammation thereby impacting kidney health. We investigated whether acid load estimated from urine measures is asso
Autor:
Run Yu
Publikováno v:
AACE clinical case reports, vol 9, iss 3
Background/objectiveLarge amount of protein wasting such as in nephrotic syndrome is a rare cause of high levothyroxine (LT4) replacement dose requirement. A case has been reported here that demonstrates that protein-losing enteropathy is a novel and
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Autor:
Yang Hu, Mimansa Geere, Maham Awan, Andrew D. Leavitt, Laura E. Brown, Hadley J. Pearson, Jocelyn S. Gandelman, Scott C. Kogan
Publikováno v:
Hematology (Amsterdam, Netherlands), vol 27, iss 1
BackgroundThe appearance of bite cells associated with methemoglobinemia can be caused by oxidizing drugs such as dapsone in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or high drug serum levels. Bite cells are often pathognomon
Autor:
Jun Zhang, Melissa Johnson, Minal Barve, Lyudmila Bazhenova, Marybeth McCarthy, Rowena Schwartz, Elise Horvath-Walsh, Karen Velastegui, Chunlin Qian, Alexander Spira
Publikováno v:
The oncologist, vol 28, iss 4
Adagrasib (MRTX849) is a KRASG12C inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with KRASG12C-muta
Autor:
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara
Publikováno v:
Dermatology and Therapy, 13(5), 1099-1111. Springer-Verlag
Dermatology and therapy, vol 13, iss 5
Dermatology and therapy, vol 13, iss 5
IntroductionHidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and safety of
Autor:
Paul J. Hartman, David L. Cooke, Henry H. Hsu, Jeanette Stewart, Kengo Sumi, Yoko Yoshida, Hiroyoshi Hidaka, Gary D. Novack
Publikováno v:
Ophthalmology. Glaucoma, vol 6, iss 2
PurposeTo perform a phase Ⅰ/Ⅱ evaluation of an H-1337 ophthalmic solution in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).DesignThis was a phase I/II, randomized, double-masked, vehicle-controlled, dose-response s
Autor:
Schmid, Peter, Wysocki, Piotr, Ma, Cynthia, Park, Yeon H, Fernandes, Ricardo, Lord, Simon, Baird, Richard D, Prady, Catherine, Jung, Kyung Hae, Asselah, Jamil, Huisden, Robert, Stewart, Ross, Vuković, Petra, Nunes, Ana T, Nowecki, Zbigniew
Publikováno v:
Cancer Research. 83:PD11-09
Background: Patients with a/mTNBC have limited treatment options and a poor prognosis (objective response rate [ORR] of 37%, median duration of response 6.5 months, median overall survival 15.5 months for 1L chemotherapy [Rugo, et al. Ann Oncol. 2021
Autor:
Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie W. Taylor, Elizabeth A. Maher, Isabel Arrillaga-Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Ania Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer L. Clarke, Timothy F. Cloughesy
Publikováno v:
Nature medicine, vol 29, iss 3
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recur